⚠ Evidence note: Human outcome data on longevity interventions is limited; most claims rest on surrogate markers or animal models. Nothing here is medical advice.
TJ0113 Capsule
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-08-05 — Clinical Study of TJ0113 Capsule in the Treatment of Patients With Sarcopenia: Phase II multicenter, randomized, double-blind, placebo-controlled trial registered to test TJ0113 capsule at 100/200/400 mg daily for 26 weeks in 204 sarcopenia patients (1:1:1:1 vs placebo); protocol registration only, no efficacy or safety readout yet. [human-rct] (novelty: 3)
Open questions
Related
Contributing findings
Clinical Study of TJ0113 Capsule in the Treatment of Patients With Sarcopenia
05-aug-2026
novelty 3
per-area 3
strengthens